No abstract available
Keywords:
BK polyomavirus; kidney transplantation (KT); liver transplantation (LT); randomised controlled trial; systematic review/Meta-analysis.
PubMed Disclaimer
Conflict of interest statement
SK has received consultancy fees from OrganOx Ltd for assistance in clinical study design. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
-
Bowman LJ, Brueckner AJ, Doligalski CT. The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature. Transplantation (2018) 102:S50–S59. 10.1097/TP.0000000000001777
-
DOI
-
PubMed
-
-
Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR Regulates Memory CD8 T-Cell Differentiation. Nature (2009) 460:108–12. 10.1038/nature08155
-
DOI
-
PMC
-
PubMed
-
-
Hahn D, Hodson EM, Hamiwka LA, Lee VW, Chapman JR, Craig JC, et al. Target of Rapamycin Inhibitors (TOR-I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients. The Cochrane Database Syst Rev (2019) 12:CD004290. 10.1002/14651858.CD004290.pub3
-
DOI
-
PMC
-
PubMed
-
-
Wajih Z, Karpe KM, Walters GD. Interventions for BK Virus Infection in Kidney Transplant Recipients. The Cochrane Database Syst Rev (2024) 10:CD013344. 10.1002/14651858.CD013344.pub2
-
DOI
-
PMC
-
PubMed
-
-
Caillard S, Meyer N, Solis M, et al. Insights from the BKEVER Trial Comparing Everolimus versus Mycophenolate Mofetil for BK Polyomavirus Infection in Kidney Transplant Recipients. Kidney Int (2024) S0085. 10.1016/j.kint.2024.09.018
-
DOI
-
PubMed